CMIO-OLNZ

CMIO-OLNZ is an investigational **transdermal olanzapine patch** being developed by **ChemioCare** for the treatment of **PARP inhibitor induced nausea and vomiting** in cancer patients receiving PARP inhibitors. It is a **7-day matrix transdermal delivery system** designed to maintain sustained systemic exposure to olanzapine, an atypical antipsychotic with antiemetic activity, while aiming to reduce sedation relative to conventional use. Olanzapine exerts its pharmacology through antagonism at multiple neurotransmitter receptors, including **dopamine D2** and **serotonin 5-HT2A and 5-HT2C receptors**, with additional activity at other serotonergic, histaminergic, muscarinic, and adrenergic receptors that likely contribute to its antiemetic profile. Based on the provided context, CMIO-OLNZ completed a first-in-woman bioavailability study and was described as **Phase 3-ready** as of December 2019 for this unmet-need supportive care indication.

Other names

olanzapine transdermal patch7-day matrix transdermal olanzapine